Sanara MedTech 

$21.69
18
+$0.88+4.23% 今天

統計

當日最高
22.5
當日最低
20.62
52週高點
35.95
52週低點
16.05
成交量
1,090,776
平均成交量
-
市值
193.82M
本益比
374
股息殖利率
-
股息
-

即將到來

財報

17Aug預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
下一步
-3.4
-2.25
-1.11
0.04
預期EPS
-0.025
實際EPS
不適用

財務

-11.15%利潤率
未盈利
2019
2020
2021
2022
2023
2024
173.34M營收
-19.33M淨利

分析師評級

34.00平均目標價
最高預估為 36.00。
來自過去6個月內的 2 則評分。這不是投資建議。
買入
100%
持有
0%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 SMTI 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Show more...
執行長
Mr. Ronald T. Nixon
員工
141
國家
美國
ISIN
US79957L1008

上市

0 Comments

分享你的想法

FAQ

Sanara MedTech 今天的股價是多少?
SMTI 目前價格為 $21.69 USD,過去 24 小時上漲了 +4.23%。在圖表上更密切關注 Sanara MedTech 股價表現。
Sanara MedTech 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Sanara MedTech 的股票以代號 SMTI 進行交易。
Sanara MedTech 的股價在上漲嗎?
SMTI 股票較上週下跌 -1.18%,本月上漲 +3.66%,過去一年 Sanara MedTech 下跌 -24.23%。
Sanara MedTech 的市值是多少?
今天 Sanara MedTech 的市值為 193.82M
Sanara MedTech 下一次財報日期是什麼時候?
Sanara MedTech 將於 August 17, 2026 公布下一次財報。
Sanara MedTech 上一季度的財報如何?
SMTI 上一季度的財報為每股 0.04 USD,預估為 -0.13 USD,帶來 +130.77% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Sanara MedTech 去年的營收是多少?
Sanara MedTech 去年的營收為 173.34MUSD。
Sanara MedTech 去年的淨利是多少?
SMTI 去年的淨收益為 -19.33MUSD。
Sanara MedTech 有多少名員工?
截至 June 15, 2026,公司共有 141 名員工。
Sanara MedTech 位於哪個產業?
Sanara MedTech從事於Health & Wellness產業。
Sanara MedTech 何時完成拆股?
Sanara MedTech 上次拆股發生於 May 10, 2019,比例為 1:100。
Sanara MedTech 的總部在哪裡?
Sanara MedTech 的總部位於 美國 的 Fort Worth。